Graham Simmons

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6996449/publications.pdf

Version: 2024-02-01

116 papers	11,649 citations	36691 53 h-index	34195 103 g-index
135 all docs	135 docs citations	135 times ranked	15840 citing authors

#	Article	IF	Citations
1	Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program. Clinical Infectious Diseases, 2022, 74, 871-881.	2.9	32
2	Antibody profiles in <scp>COVID</scp>â€19 convalescent plasma prepared with amotosalen/<scp>UVA</scp> pathogen reduction treatment. Transfusion, 2022, 62, 570-583.	0.8	8
3	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell Reports, 2022, 39, 110815.	2.9	0
4	The Tetraspanin CD81 Is a Host Factor for Chikungunya Virus Replication. MBio, 2022, 13, .	1.8	8
5	Mitigating the risk of transfusionâ€transmitted infections with vectorâ€borne agents solely by means of pathogen reduction. Transfusion, 2022, 62, 1388-1398.	0.8	10
6	Chikungunya virus assembly and budding visualized in situ using cryogenic electron tomography. Nature Microbiology, 2022, 7, 1270-1279.	5.9	21
7	Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 323, L372-L389.	1.3	9
8	SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nature Communications, 2021, 12, 541.	5.8	66
9	Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. MAbs, 2021, 13, 1893426.	2.6	22
10	Selecting COVID â€19 convalescent plasma for neutralizing antibody potency using a highâ€capacity SARSâ€CoV â€2 antibody assay. Transfusion, 2021, 61, 1160-1170.	0.8	18
11	<scp>SARSâ€CoV</scp>â€2 antibody persistence in <scp>COVID</scp>â€19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion, 2021, 61, 2677-2687.	0.8	46
12	Human IFITM3 restricts chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction. Life Science Alliance, 2021, 4, e202000909.	1.3	10
13	The Specificity of the Persistent IgM Neutralizing Antibody Response in Zika Virus Infections among Individuals with Prior Dengue Virus Exposure. Journal of Clinical Microbiology, 2021, 59, e0040021.	1.8	6
14	Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab385.	0.4	3
15	Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA - Journal of the American Medical Association, 2021, 326, 1400.	3.8	160
16	Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. Journal of Virology, 2021, 95, e0061921.	1.5	4
17	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiology Spectrum, 2021, 9, e0139721.	1.2	15
18	Seroreactivity against Marburg or related filoviruses in West and Central Africa. Emerging Microbes and Infections, 2020, 9, 124-128.	3.0	8

#	Article	IF	Citations
19	Evolving viral and serological stages of Zika virus RNA-positive blood donors and estimation of incidence of infection during the 2016 Puerto Rican Zika epidemic: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 1437-1445.	4.6	17
20	Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study. Lancet Infectious Diseases, The, 2020, 20, 1446-1456.	4.6	39
21	Decontamination of SARS-CoV-2 and Other RNA Viruses from N95 Level Meltblown Polypropylene Fabric Using Heat under Different Humidities. ACS Nano, 2020, 14, 14017-14025.	7.3	69
22	SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nature Communications, 2020, 11, 4698.	5.8	124
23	A 3.4-Ã… cryo-electron microscopy structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles. QRB Discovery, 2020, 1, e11.	0.6	10
24	Antigenicity, stability, and reproducibility of Zika reporter virus particlesÂfor long-term applications. PLoS Neglected Tropical Diseases, 2020, 14, e0008730.	1.3	9
25	Establishment of an Alphavirus-Specific Neutralization Assay to Distinguish Infections with Different Members of the Semliki Forest complex. Viruses, 2019, 11, 82.	1.5	25
26	Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins. Cell Reports, 2019, 27, 2092-2104.e10.	2.9	112
27	Serologic Prevalence of Ebola Virus in Equatorial Africa. Emerging Infectious Diseases, 2019, 25, 911-918.	2.0	18
28	Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus. Viruses, 2019, 11, 305.	1.5	32
29	Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential. Scientific Reports, 2019, 9, 20399.	1.6	35
30	Serologic Markers for Ebolavirus Among Healthcare Workers in the Democratic Republic of the Congo. Journal of Infectious Diseases, 2019, 219, 517-525.	1.9	13
31	Arbovirus Diagnostics: From Bad to Worse due to Expanding Dengue Virus Vaccination and Zika Virus Epidemics. Clinical Infectious Diseases, 2018, 66, 1181-1183.	2.9	14
32	Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. Journal of Infectious Diseases, 2018, 217, 223-231.	1.9	52
33	An attenuated replication-competent chikungunya virus with a fluorescently tagged envelope. PLoS Neglected Tropical Diseases, 2018, 12, e0006693.	1.3	8
34	Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane. Cell Host and Microbe, 2018, 24, 417-428.e5.	5.1	56
35	Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors. Journal of Infectious Diseases, 2018, 218, 1929-1936.	1.9	16
36	Susceptibility of Chikungunya Virus to Inactivation by Heat and Commercially and World Health Organization-Recommended Biocides. Journal of Infectious Diseases, 2018, 218, 1507-1510.	1.9	2

#	Article	IF	Citations
37	First cases of Zika virusâ€“infected US blood donors outside states with areas of active transmission. Transfusion, 2017, 57, 770-778.	0.8	59
38	Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests. Clinical Infectious Diseases, 2017, 65, 1829-1836.	2.9	66
39	Higher Serum Alanine Transaminase Levels in Male Urokinase-Type Plasminogen Activator-Transgenic Mice are Associated with Improved Engraftment of Hepatocytes but not Liver Sinusoidal Endothelial Cells. Cell Medicine, 2017, 9, 117-125.	5.0	3
40	Zika Virus Tissue and Blood Compartmentalization in Acute Infection of Rhesus Macaques. PLoS ONE, 2017, 12, e0171148.	1.1	102
41	High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014. Emerging Infectious Diseases, 2016, 22, 1221-1228.	2.0	87
42	Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic. Journal of Infectious Diseases, 2016, 214, 49-54.	1.9	59
43	Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms. Vaccine Journal, 2016, 23, 535-539.	3.2	8
44	Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins. Current Gene Therapy, 2016, 16, 47-55.	0.9	32
45	Interferon-Induced Transmembrane Proteinâ€“Mediated Inhibition of Host Cell Entry of Ebolaviruses. Journal of Infectious Diseases, 2015, 212, S210-S218.	1.9	58
46	EMERGING RHABDOVIRUSES. , 2015, , 311-334.		1
47	Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Reports, 2015, 13, 2553-2564.	2.9	86
48	Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research, 2015, 116, 76-84.	1.9	513
49	Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell, 2015, 163, 1095-1107.	13.5	157
50	Human keratinocytes restrict chikungunya virus replication at a post-fusion step. Virology, 2015, 476, 1-10.	1.1	29
51	Exposure of Epitope Residues on the Outer Face of the Chikungunya Virus Envelope Trimer Determines Antibody Neutralizing Efficacy. Journal of Virology, 2014, 88, 14364-14379.	1.5	77
52	Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion, 2013, 53, 438-454.	0.8	58
53	Filovirus Entry. Advances in Experimental Medicine and Biology, 2013, 790, 83-94.	0.8	13
54	Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Research, 2013, 100, 605-614.	1.9	354

#	Article	IF	Citations
55	A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease. PLoS Neglected Tropical Diseases, 2013, 7, e2423.	1.3	99
56	Filoviruses Utilize Glycosaminoglycans for Their Attachment to Target Cells. Journal of Virology, 2013, 87, 3295-3304.	1.5	61
57	Characterization of the Bas-Congo Virus Glycoprotein and Its Function in Pseudotyped Viruses. Journal of Virology, 2013, 87, 9558-9568.	1.5	13
58	The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies. Journal of Virology, 2013, 87, 5502-5511.	1.5	305
59	A Novel Rhabdovirus Associated with Acute Hemorrhagic Fever in Central Africa. PLoS Pathogens, 2012, 8, e1002924.	2.1	181
60	Development of novel entry inhibitors targeting emerging viruses. Expert Review of Anti-Infective Therapy, 2012, 10, 1129-1138.	2.0	48
61	In-Depth Investigation of Archival and Prospectively Collected Samples Reveals No Evidence for XMRV Infection in Prostate Cancer. PLoS ONE, 2012, 7, e44954.	1.1	35
62	Development and application of a highâ€throughput microneutralization assay: lack of xenotropic murine leukemia virusâ€"related virus and/or murine leukemia virus detection in blood donors. Transfusion, 2012, 52, 332-342.	0.8	11
63	Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types. Journal of Virological Methods, 2012, 179, 127-134.	1.0	4
64	Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. Journal of General Virology, 2012, 93, 1673-1679.	1.3	8
65	Flexible antibodies with nonprotein hinges. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2011, 87, 603-616.	1.6	7
66	The Blood Xenotropic Murine Leukemia Virusâ€"Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion, 2011, 51, 643-653.	0.8	32
67	Different host cell proteases activate the SARS-coronavirus spike-protein for cellâ€"cell and virusâ€"cell fusion. Virology, 2011, 413, 265-274.	1.1	114
68	Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Research, 2011, 90, 22-32.	1.9	71
69	Inhibitors of SARS-CoV entry â€" Identification using an internally-controlled dual envelope pseudovirion assay. Antiviral Research, 2011, 92, 187-194.	1.9	21
70	Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease. Journal of Virology, 2011, 85, 13363-13372.	1.5	259
71	Failure to Confirm XMRV/MLVs in the Blood of Patients with Chronic Fatigue Syndrome: A Multi-Laboratory Study. Science, 2011, 334, 814-817.	6.0	93
72	No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected. Science, 2011, 333, 94-97.	6.0	108

#	Article	IF	Citations
73	No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome. PLoS ONE, 2011, 6, e27870.	1.1	14
74	No Evidence of Murine Leukemia Virus-Related Viruses in Live Attenuated Human Vaccines. PLoS ONE, 2011, 6, e29223.	1.1	11
75	Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Current Opinion in Hematology, 2010, 17, 550-557.	1.2	9
76	Absence of evidence of Xenotropic Murine Leukemia Virus-related virus infection in persons with Chronic Fatigue Syndrome and healthy controls in the United States. Retrovirology, 2010, 7, 57.	0.9	126
77	A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms. Journal of Virology, 2010, 84, 8753-8764.	1.5	127
78	Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. Journal of Virology, 2010, 84, 1198-1205.	1.5	429
79	Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2. Retrovirology, 2010, 7, 47.	0.9	34
80	Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology, 2009, 393, 33-41.	1.1	67
81	Proteolysis of the Ebola Virus Glycoproteins Enhances Virus Binding and Infectivity. Journal of Virology, 2007, 81, 13378-13384.	1.5	154
82	Highly Conserved Regions within the Spike Proteins of Human Coronaviruses 229E and NL63 Determine Recognition of Their Respective Cellular Receptors. Journal of Virology, 2006, 80, 8639-8652.	1.5	101
83	The Signal Peptide of the Ebolavirus Glycoprotein Influences Interaction with the Cellular Lectins DC-SIGN and DC-SIGNR. Journal of Virology, 2006, 80, 6305-6317.	1.5	51
84	Expanded Tropism and Altered Activation of a Retroviral Glycoprotein Resistant to an Entry Inhibitor Peptide. Journal of Virology, 2006, 80, 353-359.	1.5	9
85	Endosomal Proteolysis by Cathepsins Is Necessary for Murine Coronavirus Mouse Hepatitis Virus Type 2 Spike-Mediated Entry. Journal of Virology, 2006, 80, 5768-5776.	1.5	142
86	Proteolysis of Sars-Associated Coronavirus Spike Glycoprotein. Advances in Experimental Medicine and Biology, 2006, 581, 235-240.	0.8	12
87	Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes. Emerging Infectious Diseases, 2005, 11, 411-416.	2.0	152
88	Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11876-11881.	3.3	935
89	Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4240-4245.	3.3	491
90	Biological Analysis of Human Immunodeficiency Virus Type 1 R5 Envelopes Amplified from Brain and Lymph Node Tissues of AIDS Patients with Neuropathology Reveals Two Distinct Tropism Phenotypes and Identifies Envelopes in the Brain That Confer an Enhanced Tropism and Fusigenicity for Macrophages. Journal of Virology, 2004, 78, 6915-6926.	1.5	177

#	Article	IF	Citations
91	Identification of murine T-cell epitopes in Ebola virus nucleoprotein. Virology, 2004, 318, 224-230.	1.1	25
92	DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2004, 78, 12090-12095.	1.5	357
93	DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells. Virology, 2003, 305, 115-123.	1.1	338
94	FolateReceptor Alpha and Caveolae Are Not Required for Ebola VirusGlycoprotein-Mediated ViralInfection. Journal of Virology, 2003, 77, 13433-13438.	1.5	106
95	Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR. Journal of Virology, 2003, 77, 1337-1346.	1.5	229
96	Ebola Virus Glycoproteins Induce Global Surface Protein Down-Modulation and Loss of Cell Adherence. Journal of Virology, 2002, 76, 2518-2528.	1.5	196
97	Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells. Aids, 2001, 15, 1613-1626.	1.0	12
98	Phylogenetic Analysis of Multiple Heterosexual Transmission Events Involving Subtype B of HIV Type 1. AIDS Research and Human Retroviruses, 2001, 17, 689-695.	0.5	12
99	Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunological Reviews, 2000, 177, 112-126.	2.8	117
100	KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood, 2000, 95, 1151-1157.	0.6	204
101	Chemokine Inhibition of HIV Infection. , 2000, 138, 209-222.		6
102	A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3. Journal of Biological Chemistry, 2000, 275, 25985-25992.	1.6	199
103	Differential Activation of CC Chemokine Receptors by AOP-RANTES. Journal of Biological Chemistry, 2000, 275, 7787-7794.	1.6	68
104	T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. Journal of General Virology, 2000, 81, 2899-2904.	1.3	33
105	Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo. Journal of Virology, 1999, 73, 7795-7804.	1.5	142
106	Coreceptor Ligand Inhibition of Fetal Brain Cell Infection by HIV Type 1. AIDS Research and Human Retroviruses, 1999, 15, 989-1000.	0.5	18
107	HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Molecular Membrane Biology, 1999, 16, 49-55.	2.0	47
108	Expanded Tropism of Primary Human Immunodeficiency Virus Type 1 R5 Strains to CD4 + T-Cell Lines Determined by the Capacity To Exploit Low Concentrations of CCR5. Journal of Virology, 1999, 73, 7842-7847.	1.5	49

#	Article	IF	Citations
109	Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity. Journal of Experimental Medicine, 1998, 187, 1215-1224.	4.2	399
110	CXCR4 as a Functional Coreceptor for Human Immunodeficiency Virus Type 1 Infection of Primary Macrophages. Journal of Virology, 1998, 72, 8453-8457.	1.5	140
111	Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist. Science, 1997, 276, 276-279.	6.0	654
112	A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus. Science, 1997, 277, 1656-1659.	6.0	473
113	HIV-1 tropism and co-receptor use. Nature, 1997, 385, 495-496.	13.7	151
114	CD4-Independent Infection by HIV-2 (ROD/B): Use of the 7-Transmembrane Receptors CXCR-4, CCR-3, and V28 for Entry. Virology, 1997, 231, 130-134.	1.1	166
115	Cell-to-Cell Fusion, but Not Virus Entry in Macrophages by T-Cell Line Tropic HIV-1 Strains: A V3 Loop-Determined Restriction. Virology, 1995, 209, 696-700.	1.1	49
116	Is CD4 sufficient for HIV entry? Cell surface molecules involved in HIV infection. Philosophical Transactions of the Royal Society B: Biological Sciences, 1993, 342, 67-73.	1.8	10